Arcturus Therapeutics Stock Price, Forecast & Analysis (NASDAQ:ARCT)

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Arcturus Therapeutics Ltd (NASDAQ:ARCT) issued its quarterly earnings results on Monday, May, 13th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.53) by $0.15. The biotechnology company had revenue of $4.35 million for the quarter, compared to analyst estimates of $3.47 million. Arcturus Therapeutics had a negative return on equity of 160.16% and a negative net margin of 63.05%. View Arcturus Therapeutics' Earnings History.

Arcturus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Arcturus Therapeutics.

5 Wall Street analysts have issued 1 year price objectives for Arcturus Therapeutics' shares. Their forecasts range from $18.00 to $18.00. On average, they anticipate Arcturus Therapeutics' share price to reach $18.00 in the next year. This suggests a possible upside of 89.7% from the stock's current price. View Analyst Price Targets for Arcturus Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcturus Therapeutics.

News stories about ARCT stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arcturus Therapeutics earned a daily sentiment score of 1.1 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Arcturus Therapeutics.

Arcturus Therapeutics saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 88,400 shares, a decrease of 14.9% from the September 30th total of 103,900 shares. Based on an average daily volume of 78,800 shares, the short-interest ratio is currently 1.1 days. Currently, 1.3% of the shares of the company are short sold. View Arcturus Therapeutics' Current Options Chain.

Some companies that are related to Arcturus Therapeutics include Akorn (AKRX), XBiotech (XBIT), ChemoCentryx (CCXI), Kadmon (KDMN), Intra-Cellular Therapies (ITCI), Progenics Pharmaceuticals (PGNX), Stemline Therapeutics (STML), ImmunoGen (IMGN), Synthorx (THOR), Aurinia Pharmaceuticals (AUPH), Dynavax Technologies (DVAX), Cytokinetics (CYTK), Frequency Therapeutics (FREQ), Basilea Pharmaceutica (BPMUF) and AC Immune (ACIU).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Opko Health (OPK), KLA-Tencor (KLAC), Energy Transfer LP Unit (ET), Terravia (TVIAQ), Corbus Pharmaceuticals (CRBP), Obsidian Energy (OBE), Abeona Therapeutics (ABEO), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO) and Rexahn Pharmaceuticals (REXN).

Arcturus Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Dfpg Investments Inc. (3.23%), Sumitomo Mitsui Trust Holdings Inc. (2.09%), Nikko Asset Management Americas Inc. (2.09%) and We Are One Seven LLC (0.10%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Magda Marquet and Peter C Farrell. View Institutional Ownership Trends for Arcturus Therapeutics.

ARCT stock was acquired by a variety of institutional investors in the last quarter, including Dfpg Investments Inc., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc. and We Are One Seven LLC. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Magda Marquet and Peter C Farrell. View Insider Buying and Selling for Arcturus Therapeutics.

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARCT stock can currently be purchased for approximately $9.49.

Arcturus Therapeutics has a market capitalization of $143.58 million and generates $15.75 million in revenue each year. The biotechnology company earns $-21,780,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. Arcturus Therapeutics employs 72 workers across the globe.View Additional Information About Arcturus Therapeutics.

The official website for Arcturus Therapeutics is http://www.arcturusrx.com/.

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]